This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Bayer Healthcare Aktiengesellschaft. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008
Title: Wayne A. Froland: Innovator in Diabetes Treatment
Introduction
Wayne A. Froland is a notable inventor based in Alameda, CA, who has made significant contributions to the field of diabetes treatment. His innovative work focuses on developing peptides that can effectively lower blood glucose levels in patients, particularly those suffering from type 2 diabetes.
Latest Patents
Wayne A. Froland holds a patent for the invention titled "Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonist peptide." This invention provides novel peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptides have been shown to lower blood glucose in vivo more than controls upon glucose challenge. The polypeptides are stable in formulation and possess long half-lives. This invention offers a new therapy for patients with decreased endogenous insulin secretion, specifically targeting type 2 diabetics. The invention includes a polypeptide selected from a specific group of VPAC2-related polypeptides or functional equivalents thereof. Additionally, it outlines a method for treating metabolic diseases in mammals by administering a therapeutically effective amount of the insulin secretagogue peptides. Methods for making the peptides, both recombinant and synthetic, are also disclosed.
Career Highlights
Wayne A. Froland is associated with Bayer Healthcare Aktiengesellschaft, where he continues to contribute to advancements in medical science. His work has been pivotal in developing therapies that address critical health issues related to insulin secretion and glucose regulation.
Collaborations
Wayne has collaborated with notable colleagues, including Michael L. Dumas and James Whelan, who have also contributed to the field of diabetes research and treatment.
Conclusion
Wayne A. Froland's innovative work in developing VPAC2 receptor agonist peptides represents a significant advancement in diabetes treatment. His contributions are vital for improving the lives of patients with type 2 diabetes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile